5:32 PM
 | 
Feb 25, 2013
 |  BC Extra  |  Clinical News

Merck's cilengitide misses in Phase III for glioblastoma multiforme

The EMD Serono Inc. subsidiary of Merck KGaA (Xetra:MRK) said twice-weekly IV cilengitide plus standard radiation and Temodar temozolomide therapy missed the primary endpoint of improving overall survival (OS) vs....

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >